newsfilter
← Latest News
GlobeNewswire·

Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)

- First potentially disease-modifying gene therapy for GM2 gangliosidosis to enter clinical studies- Expect to continue patient identification, screening, and enrollment in Stage 1 of the study...